Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

2019245 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: The Lancet Haematology

Volume 6, Issue 5, pp. e254-e265

Field-Weighted Citation Impact: 22.12